Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H10O5 |
Molecular Weight | 258.2262 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=CC=CC=C1OC(=O)C2=CC=CC=C2O
InChI
InChIKey=WVYADZUPLLSGPU-UHFFFAOYSA-N
InChI=1S/C14H10O5/c15-11-7-3-1-5-9(11)14(18)19-12-8-4-2-6-10(12)13(16)17/h1-8,15H,(H,16,17)
DescriptionSources: https://www.drugs.com/pro/salsalate.htmlCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23817699 |
https://www.ncbi.nlm.nih.gov/pubmed/6520777
Sources: https://www.drugs.com/pro/salsalate.html
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23817699 |
https://www.ncbi.nlm.nih.gov/pubmed/6520777
Salsalate is a dimer of salicylic acid. Upon administration, it is metabolically hydrolyzed to salicylic acid. Salsalate is is a nonsteroidal anti-inflammatory agent for oral administration for treatment of rheumatoid arthritis, osteoarthritis and related rheumatoid disorders. In addition, salsalate is investigated for treatment of type 2 diabetes.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0001516 Sources: Salsalate selectively inhibits prostaglandin synthesis in vivo |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | DISALCID Approved UseSalsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, and related rheumatic disorder. |
|||
Palliative | DISALCID Approved UseSalsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorder. |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Aspirin and NSAID sensitivity. | 2004 Aug |
|
Drugs associated with more suicidal ideations are also associated with more suicide attempts. | 2009 Oct 2 |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
2009 World Congress on the Insulin Resistance Syndrome: cardiovascular disease concepts. | 2010 Jul |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/salsalate.html
The usual dosage is 3000 mg daily, given in divided doses as follows: 1(two doses of two 750 mg tablets; 2) two doses of three 500 mg tablets; or 3) three doses of two 500 mg tablets.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
N02BA06
Created by
admin on Fri Dec 15 15:10:17 UTC 2023 , Edited by admin on Fri Dec 15 15:10:17 UTC 2023
|
||
|
WHO-VATC |
QN02BA06
Created by
admin on Fri Dec 15 15:10:17 UTC 2023 , Edited by admin on Fri Dec 15 15:10:17 UTC 2023
|
||
|
LIVERTOX |
NBK548843
Created by
admin on Fri Dec 15 15:10:17 UTC 2023 , Edited by admin on Fri Dec 15 15:10:17 UTC 2023
|
||
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 15:10:17 UTC 2023 , Edited by admin on Fri Dec 15 15:10:17 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
49171
Created by
admin on Fri Dec 15 15:10:17 UTC 2023 , Edited by admin on Fri Dec 15 15:10:17 UTC 2023
|
PRIMARY | |||
|
Salsalate
Created by
admin on Fri Dec 15 15:10:17 UTC 2023 , Edited by admin on Fri Dec 15 15:10:17 UTC 2023
|
PRIMARY | |||
|
100000086562
Created by
admin on Fri Dec 15 15:10:17 UTC 2023 , Edited by admin on Fri Dec 15 15:10:17 UTC 2023
|
PRIMARY | |||
|
9014
Created by
admin on Fri Dec 15 15:10:17 UTC 2023 , Edited by admin on Fri Dec 15 15:10:17 UTC 2023
|
PRIMARY | |||
|
36108
Created by
admin on Fri Dec 15 15:10:17 UTC 2023 , Edited by admin on Fri Dec 15 15:10:17 UTC 2023
|
PRIMARY | RxNorm | ||
|
209-027-4
Created by
admin on Fri Dec 15 15:10:17 UTC 2023 , Edited by admin on Fri Dec 15 15:10:17 UTC 2023
|
PRIMARY | |||
|
CHEMBL154111
Created by
admin on Fri Dec 15 15:10:17 UTC 2023 , Edited by admin on Fri Dec 15 15:10:17 UTC 2023
|
PRIMARY | |||
|
DB01399
Created by
admin on Fri Dec 15 15:10:17 UTC 2023 , Edited by admin on Fri Dec 15 15:10:17 UTC 2023
|
PRIMARY | |||
|
2420
Created by
admin on Fri Dec 15 15:10:17 UTC 2023 , Edited by admin on Fri Dec 15 15:10:17 UTC 2023
|
PRIMARY | |||
|
SUB10434MIG
Created by
admin on Fri Dec 15 15:10:17 UTC 2023 , Edited by admin on Fri Dec 15 15:10:17 UTC 2023
|
PRIMARY | |||
|
5161
Created by
admin on Fri Dec 15 15:10:17 UTC 2023 , Edited by admin on Fri Dec 15 15:10:17 UTC 2023
|
PRIMARY | |||
|
m9747
Created by
admin on Fri Dec 15 15:10:17 UTC 2023 , Edited by admin on Fri Dec 15 15:10:17 UTC 2023
|
PRIMARY | Merck Index | ||
|
SALSALATE
Created by
admin on Fri Dec 15 15:10:17 UTC 2023 , Edited by admin on Fri Dec 15 15:10:17 UTC 2023
|
PRIMARY | |||
|
DTXSID1023572
Created by
admin on Fri Dec 15 15:10:17 UTC 2023 , Edited by admin on Fri Dec 15 15:10:17 UTC 2023
|
PRIMARY | |||
|
3267
Created by
admin on Fri Dec 15 15:10:17 UTC 2023 , Edited by admin on Fri Dec 15 15:10:17 UTC 2023
|
PRIMARY | |||
|
V9MO595C9I
Created by
admin on Fri Dec 15 15:10:17 UTC 2023 , Edited by admin on Fri Dec 15 15:10:17 UTC 2023
|
PRIMARY | |||
|
V9MO595C9I
Created by
admin on Fri Dec 15 15:10:17 UTC 2023 , Edited by admin on Fri Dec 15 15:10:17 UTC 2023
|
PRIMARY | |||
|
C014182
Created by
admin on Fri Dec 15 15:10:17 UTC 2023 , Edited by admin on Fri Dec 15 15:10:17 UTC 2023
|
PRIMARY | |||
|
552-94-3
Created by
admin on Fri Dec 15 15:10:17 UTC 2023 , Edited by admin on Fri Dec 15 15:10:17 UTC 2023
|
PRIMARY | |||
|
1609807
Created by
admin on Fri Dec 15 15:10:17 UTC 2023 , Edited by admin on Fri Dec 15 15:10:17 UTC 2023
|
PRIMARY | |||
|
C62636
Created by
admin on Fri Dec 15 15:10:17 UTC 2023 , Edited by admin on Fri Dec 15 15:10:17 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)